The NLRP3 Inflammasome and Pro-Inflammatory Cytokines in Alzheimer's Disease: Molecular Mechanisms, Neuroimmune Crosstalk, Biomarkers, and Emerging Therapeutic Perspectives
Aug 2026· Scholars International Journal of Biochemistry· 0 citations
TL;DR
The molecular mechanisms underlying NLRP3 inflammasome activation in Alzheimer’s disease, its interaction with pro-inflammatory cytokine networks, and the emerging role of inflammasome-related biomarkers in disease characterization are examined.
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, characterized by progressive cognitive decline, memory impairment, and behavioral dysfunction. Despite extensive research, effective disease-modifying therapies remain limited, largely due to incomplete understanding of its complex and multifactorial pathogenesis. Increasing evidence now highlights chronic neuroinflammation as a central contributor to AD progression, shifting focus from a purely proteinopathy-based model toward an integrated neuroimmune perspective. Among key inflammatory pathways, the NLRP3 inflammasome has emerged as a critical innate immune signaling platform that links pathological protein aggregation to sustained neuroinflammatory responses in the central nervous system. Activation of the NLRP3 inflammasome is triggered by multiple Alzheimer’s disease–associated pathological stimuli, including amyloid-β accumulation, tau pathology, autophagy dysfunction, mitochondrial impairment, oxidative stress, and endoplasmic reticulum stress. These cellular disturbances converge to promote assembly of the inflammasome complex and activation of caspase-1. Activated caspase-1 mediates the proteolytic maturation and release of the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18), both of which play central roles in amplifying neuroinflammatory signaling, promoting synaptic dysfunction, and contributing to neuronal injury. Consequently, IL-1β and IL-18 have gained increasing attention as potential biomarkers for disease severity, progression, and inflammatory burden in Alzheimer’s disease. In addition, inflammasome-specific markers such as apoptosis-associated speck-like protein containing CARD (ASC) specks provide further mechanistic and diagnostic evidence of active inflammasome signaling in neurodegeneration. Preclinical studies using cellular and animal models have demonstrated that pharmacological inhibition of the NLRP3 inflammasome can reduce neuroinflammation, attenuate neuropathological changes, and improve cognitive performance. However, despite these promising findings, clinical translation remains limited due to challenges including inadequate blood–brain barrier penetration, systemic immune modulation risks, and the absence of reliable biomarker-guided patient stratification strategies. This review critically examines the molecular mechanisms underlying NLRP3 inflammasome activation in Alzheimer’s disease, its interaction with pro-inflammatory cytokine networks, and the emerging role of inflammasome-related biomarkers in disease characterization. Furthermore, current therapeutic strategies targeting the NLRP3 pathway are discussed, along with key translational barriers and future directions for developing biomarker-driven immunomodulatory therapies in Alzheimer’s disease.
Alzheimer's disease (AD) is the leading cause of dementia, yet current therapies provide limited clinical benefit. Neuroinflammation, as an early and sustained driver of AD, places the NLRP3 inflammasome at the center of pathological and therapeutic focus. In this review, we synthesize recent advances in the structure, assembly, and activation of the NLRP3 inflammasome, and evaluate its contribution to AD using evidence from human brain tissues, cerebrospinal fluid, and diverse AD animal models. Available data consistently support aberrant NLRP3 activation in AD brain, where it is closely associated with amyloid-β (Aβ) deposition, tau pathology, glial reactivity, and cognitive decline. We further discuss the cell-type-specific roles of microglia and astrocytes, highlighting microglia as the principal effector cells in inflammasome-associated pathology. Mechanistically, Aβ and tau converge on NLRP3 activation through interconnected pathways involving K+ efflux, lysosomal rupture, mitochondrial dysfunction, and impaired autophagy. Downstream IL-1β, IL-18, and gasdermin D amplify neuroinflammation and neuronal injury. We summarize emerging therapeutic strategies directly targeting its core components or downstream effectors, as well as anti-AD agents with indirect NLRP3 modulation including endogenous molecules, repurposed drugs, and natural products. Collectively, this review regards NLRP3 inflammasome as a critical inflammatory hub and a promising target for disease-modifying therapy in AD, and provide useful perspectives on AD pathogenesis and inform the development of more rational therapeutic strategies.
Wenwen Lian, Fulin Zhou, Zhuohang Tong et al.· Ageing Research Reviews· 0 citations
INTRODUCTION
Alzheimer's disease (AD) is a rising global health problem, but current treatments only target symptoms rather than fixing their underlying root causes. A major pathological feature is neuroinflammation, which is specifically driven by the Nucleotide-binding domain, Leucine-rich-repeat and Pyrin domain-containing 3 (NLRP3) inflammasome cascade, which acts as a 'molecular switch' that causes immune cells in the brain to trigger robust secretion of pro-inflammatory cytokines (e.g. IL-1β, IL-18) and pyroptosis, causing systemic inflammation, thereby the neuroinflammation.
AREAS COVERED
This review breaks down the pathways triggered by immune cells activation (neurotoxic microglial phenotype) and majorly focusing over the NLRP3 inflammasome neuroinflammation pathway. It explores the promising therapeutic potential of specific bioactive phytochemicals, repurposed and novel synthetic drugs/agents, to shut-down this molecular switch i.e. NLRP3 inflammasome pathway.
EXPERT OPINION
To truly stop AD, we must shift our focus from treating merely the symptoms, by stopping the disease at its roots. While discovering the novel NLRP3 inflammasome inhibitors is exciting, but the biggest hurdle is getting them into the brain. Future of AD treatment relies on combining these targeted drugs with advanced nanotechnology, like nano-particles, to successfully cross the blood-brain barrier (BBB) and safely deliver the drugs exactly where they are needed.
A. Najmi, Devesh Yaduvanshi, Rishabh Aggarwal et al.· Expert opinion on therapeuti...· 0 citations
New knowledge about the protective and detrimental aspects of neuroinflammation in AD and PD is summarized, providing an analysis on these developing prospects for targeted interventions toward slowing or stopping neurodegeneration.
R. Kumar, Kamaljeet, Sourabh Kosey· InflammoPharmacology· 0 citations
Alzheimer’s disease (AD) is the most common cause of dementia and major public-health challenge in aging societies worldwide. Accumulating evidence suggests that olfactory and visual deficits can precede overt cognitive symptoms and are closely associated with amyloid-β deposition, pathological tau phosphorylation, and disease progression. Early sensory abnormalities in AD likely arise from converging pathological processes. Among these, chronic neuroinflammation marked by microglial and astrocytic reactivity, inflammasome activation and increased pro-inflammatory mediators might play a pivotal role linking sensory-circuit injury to neurodegeneration. A coherent synthesis of the inflammatory mechanisms underlying early olfactory and visual impairment in AD remains limited, and putative molecular pathways and interventions have not been fully integrated. We aimed to identify AD-related olfactory and visual or retinal abnormalities, combine core inflammatory pathways and their interactions with amyloid-β and tau pathology, and summarize actionable targets and candidate interventions along a “receptor–intracellular signaling-inflammasome-effector” axis, to inform earlier-stage detection and mechanism-guided intervention in AD.
Yanjiao Xu, Guimei Zhang, Xinran Cui et al.· Frontiers in Aging Neuroscie...· 0 citations
Alzheimer’s disease (AD) and Parkinson’s disease (PD) represent the most prevalent chronic neurodegenerative disorders, characterized by progressive loss of neurons as a core pathological feature. Despite discrepancies in their clinical phenotypes and signature pathological proteins, accumulating evidence has validated a common molecular pathogenic mechanism: dysfunctional bidirectional crosstalk between mitophagy and inflammasomes. As the central hub of neuronal energy metabolism, mitochondrial impairment triggers the release of damage-associated molecular patterns such as reactive oxygen species and mitochondrial DNA, which in turn activate inflammasomes (e.g., NLRP3) to elicit chronic neuroinflammation. Conversely, excessive inflammasome activation suppresses mitophagy, exacerbating the accumulation of damaged mitochondria and pathological protein aggregates, and forming a pathological mitochondrial damage—inflammatory activation—autophagy inhibition cycle. Microglia and astrocytes, key immunocompetent cells of the central nervous system, act as a hub within this regulatory network. Therapeutic strategies targeting the mitophagy-inflammasome axis have achieved remarkable advancements, including mitophagy agonists, inflammasome inhibitors, and dual-target modulators. This review summarizes recent findings regarding the pathogenic roles of β-amyloid and α-synuclein in AD and PD, as well as the protective effects offered by regulating mitophagy and inflammasome activity. Furthermore, the major directions and potential hurdles in the development of targeted therapeutics are discussed, in the aim of providing insights into the novel therapeutic avenues for the treatment of both disorders.
Wei Long, Mengqin Yuan, Sirui Wang et al.· Translational Neurodegenerat...· 0 citations
Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.